Home » News » CROs/Service Providers » Covance expands global biologics capabilities

Covance expands global biologics capabilities

Monday, March 31, 2014

Covance is expanding its global bioanalytical footprint and adding scientific leaders to its biologics team. It is expanding its large-molecule bioanalytical space co-located with its central laboratory facility in Indianapolis.

The expansion, anticipated to open during the second half of 2014, is doubling the company’s large-molecule capacity and is expected to add approximately 100 new positions over the next five years.

As part of the ongoing investment in biologics, the company appointed Mike Holsapple, Ph.D., as Covance’s executive director of global immunotoxicology. Holsapple is a fellow in the Academy of Toxicological Sciences (ATS) and past president of the Society of Toxicology.

Covance also has launched molecule management teams of experienced scientific leaders who work closely with clients to develop and implement tailored solutions for the development of their biologics, which will leverage Covance’s broad portfolio of services, including discovery, preclinical, early and late clinical, central laboratories and commercialization.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!